Lv1
30 积分 2023-03-11 加入
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
10小时前
待确认
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
1天前
已完结
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
1天前
已完结
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
8天前
已完结
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
11天前
已完结
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
16天前
已完结
Machine-learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosi
16天前
已完结
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities
25天前
已完结
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
28天前
已完结
TNBC’s compass: Navigating prognosis with a cellular map
1个月前
已完结
皖公网安备34019202002308
